Saturday, June 25, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Two clever human antibodies can target Ebola and Sudan virus

by Medical Finance
in News
Scientists discover antibody that inhibits a broad range of sarbecoviruses
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Researchers at La Jolla Institute for Immunology (LJI) are designing better therapies for treating Ebola virus and its deadly relatives.

Despite the name confusion, Ebola virus is just one species in the Ebolavirus genus. There’s the Ebola virus (two words) species, and then there’s Sudan ebolavirus, Bundibugyo ebolavirus, Reston ebolavirus, Taï Forest ebolavirus and Bombali ebolavirus.

These viruses are all dangerous, but scientists so far have only developed therapies against the more well-known Ebola virus. To save lives, doctors need broad-spectrum therapies that neutralize as many Ebolavirus species as possible.

LJI President and CEO Erica Ollmann Saphire, Ph.D. and her partner Rafi Ahmed, Ph.D. at Emory University are on the hunt for human antibodies that target vulnerable sites across Ebolavirus species.

The team’s latest study, published in Cell, shows that two clever human antibodies can target two ebolavirus species at once: Ebola virus and Sudan virus. These two species are responsible for the biggest, deadliest outbreaks. The new report suggests researchers could combine these two potent antibodies to make a powerful antiviral therapy.

Finding antibodies with this breadth is important because we don’t know which virus in the genus of ebolaviruses is going to break out next.”


Erica Ollmann Saphire, Ph.D., LJI President and CEO

In addition to Saphire and Ahmed, the new research was co-led by Gabriella Worwa, D.V.M., Ph.D., of the National Institute for Allergy and Infectious Diseases. The two antibodies in this study came from survivors of Ebola virus infection who donated samples to study co-leaders at Emory University, and the Ebola monoclonal antibodies were generated by Carl Davis, Ph.D., at Emory University.

What makes these antibodies special?

To learn how these antibodies neutralize ebolaviruses, LJI Postdoctoral Fellows Xiaoying Yu, Ph.D., and Jake Milligan, Ph.D., spearheaded the use of an imaging technique called cryo-electron microscopy. This technique gave them a clear view of how the two antibodies, called 1C3 and 1C11, bind to vulnerable sites on a key ebolavirus protein, called the glycoprotein.

The team was surprised to see that 1C3 attacked the glycoprotein in an unexpected way. Instead of sticking to one site on the glycoprotein, like a key in a lock, the 1C3 lodged itself in an asymmetrical configuration, which let it block three glycoprotein sites at once.

“This antibody might punch above its weight,” says Saphire. “The antibody is able to block three sites on the virus at the same time using different loops and structures to anchor into each one. That is remarkable.”

Meanwhile, the paired antibody 1C11 binds to the fusion machinery the virus would normally use to enter and infect host cells. As Saphire explains, because the fusion machinery has such a critical job, it looks very similar between Sudan virus and Ebola virus. “This is a site of very broad recognition and resistance to any antibody escape,” she says. “That’s how this antibody gets its breadth.”

There are still four more Ebolavirus species to address, but Ebola virus and Sudan virus have caused the largest and most lethal outbreaks.

There’s one more reason these two antibodies make a dream team: They aren’t easily distracted.

While there are antibody therapies against Ebola virus, some antibodies in these therapies don’t actually neutralize the virus. Instead, the antibodies home in on a decoy protein, called soluble glycoprotein, that the virus makes.

Fortunately, 1C3 and 1C11 ignore the decoy and go straight for the virus’s actual surface glycoprotein structure. This means the researchers could use fewer antibodies to effectively target Ebola virus and Sudan virus. “If 80-90% of what’s there is some kind of smokescreen, having antibodies that can target the vulnerable spot is valuable,” Saphire says.

The two antibodies had the right stuff-;and they performed very well outside the lab. Study collaborators found that combining 1C3 and 1C11 in an antibody therapy could protect against Ebola virus and Sudan virus disease in non-human primates, reversing severe symptoms.

“These are both very potent antibodies,” says Yu.

What does this mean for patients?

The fighting power of 1C3 and 1C11 could mean more lives saved when every second matters. The broad-spectrum effects of the two antibodies makes them a promising therapy for situations when doctors don’t have time to figure out which Ebolavirus species is responsible.

Even better, these antibodies may be effective even when given late in the course of the disease. This late treatment would be extremely valuable because many patients with either Ebola virus or Sudan virus have already progressed far into infection when they are diagnosed.

“The first symptoms of Ebola virus tend to be a fever and a headache, which can look like a lot of different diseases,” Saphire says. “An antibody that can be used later in the course of disease is a lot more useful.”

Going forward, the team is trying to figure out how much lower the dosage could be. In the non-human primate trial, even the lowest dose provided 100 percent protection. Yu says a lower dose may be just as effective. This is an important question to answer because lower doses would make the therapy much cheaper to produce.

So for many reasons, a better antibody cocktail means hope for patients.

Source:

La Jolla Institute for Immunology

Journal reference:

Milligan, J.C., et al. (2022) Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell. doi.org/10.1016/j.cell.2022.02.023.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

by Medical Finance
June 25, 2022
0

New York Blood Center has published a study that reports the discovery of highly potent small molecules with the ability...

Dexamethasone administration at a late time point could enhance transgene expression

Postnatal gene therapy may be able to prevent or reverse deadly effects of Pitt-Hopkins syndrome

by Medical Finance
June 25, 2022
0

UNC School of Medicine Scientists have shown for the first time that postnatal gene therapy may be able to prevent...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Study shows how cells use octopus-like tentacles to move around the body

by Medical Finance
June 25, 2022
0

With help from the best tweezers in the world a team of researchers from the University of Copenhagen has shed...

First patient-derived stem cell model developed for studying oculocutaneous albinism

Scientists generate an atlas of human and mouse white adipocytes

by Medical Finance
June 25, 2022
0

Once considered to be inert, white adipose tissue is now recognized to be dynamic and to play an interactive role...

Study: Acidity of Expiratory Aerosols Controls the Infectivity of Airborne Influenza Virus And SARS-Cov-2. Image Credit: Aranami / Shutterstock.com

Acidity of expiratory aerosols influences infectivity of SARS-CoV-2

by Medical Finance
June 25, 2022
0

Enveloped viruses can be inactivated by exposure to acids, such as within aerosols in the atmosphere. A new study posted...

Study: Omicron Variant of SARS-COV-2 Gains New Mutations in New Zealand and Hong Kong. Image Credit: FOTOGRIN / Shutterstock.com

Omicron BA.1.1 and BA.2 subvariants with new mutations in New Zealand and Hong Kong

by Medical Finance
June 25, 2022
0

The evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the coronavirus disease 2019 (COVID-19)...

Next Post
Study: Hidden codes in mRNA: Control of gene expression by m6A. Image Credit: nobeastsofierce/Shutterstock

Gene expression regulation by N6-methyladenosine

Study: Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis. Image Credit: Exahardiwito / Shutterstock.com

COVID booster vaccination more effective relative to 2-dose series

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Plasmonic-magnetic nanorobots for SARS-CoV-2 RNA detection through electronic readout. Image Credit: Marcin Janiec / Shutterstock.com
    Detection of SARS-CoV-2 RNA by plasmonic-magnetic nanorobots
  • Pandemic 620x480
    Study reports accumulation of SARS-CoV-2 RNA in sewer biofilms
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply